Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$5.47
-0.5%
$4.63
$3.42
$7.20
$307.49M1.941.55 million shs842,110 shs
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$25.53
+4.3%
$25.08
$22.64
$53.96
$1.21B0.78481,270 shs532,528 shs
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
$40.00
$40.00
$15.25
$43.00
$1.19B1.7710,339 shsN/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$6.94
-4.9%
$7.34
$4.79
$11.78
$1.11B1.511.40 million shs1.56 million shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.00%+9.56%+14.35%+2.80%-17.42%
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
0.00%-1.29%+1.16%-23.51%-43.44%
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
0.00%0.00%0.00%0.00%+78.41%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
0.00%-2.80%-5.32%+7.83%+25.97%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.734 of 5 stars
0.02.00.00.03.80.80.6
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
4.3405 of 5 stars
3.11.00.03.74.24.21.3
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
N/AN/AN/AN/AN/AN/AN/AN/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
4.0267 of 5 stars
3.43.00.04.13.12.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
2.25
Hold$32.3326.65% Upside
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
2.00
Hold$39.25-1.88% Downside
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
2.88
Moderate Buy$16.25134.15% Upside

Current Analyst Ratings Breakdown

Latest ACB, CALT, OCUL, and AMPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2025
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral$45.00 ➝ $30.00
5/8/2025
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$40.00 ➝ $35.00
5/6/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $14.00
4/10/2025
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/8/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
4/8/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
3/21/2025
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$36.00 ➝ $32.00
3/18/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$17.00
3/11/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$15.00
3/4/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$19.00
3/4/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$320.81M0.96$0.21 per share26.35$8.18 per share0.67
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$730.66M1.66$3.56 per share7.17$13.35 per share1.91
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
$1.60B0.74N/AN/A$1.06 per share37.74
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$59.65M18.53N/AN/A$0.79 per share8.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$48.62M$0.05109.4212.43N/A0.42%0.59%0.42%6/19/2025 (Estimated)
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$137.54M$2.768.517.762.1921.80%26.44%11.89%8/6/2025 (Estimated)
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
-$80.74M-$1.15N/AN/AN/A-283.74%-45.18%-30.87%8/6/2025 (Estimated)

Latest ACB, CALT, OCUL, and AMPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/19/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11N/AN/AN/A$88.85 millionN/A
3/3/2025Q4 2024
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
-$0.24-$0.29-$0.05-$0.29$16.89 million$17.08 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
N/AN/AN/AN/AN/A
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
N/AN/AN/AN/AN/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.07
3.30
1.60
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
0.82
3.43
2.61
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
9.44
2.69
2.59
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
0.19
13.01
12.94
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,34056.21 million54.85 millionOptionable
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
1,62047.50 million35.05 millionOptionable
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
18029.79 million29.14 millionOptionable
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
230159.30 million151.71 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$5.47 -0.03 (-0.55%)
Closing price 04:00 PM Eastern
Extended Trading
$5.48 +0.01 (+0.16%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Amphastar Pharmaceuticals stock logo

Amphastar Pharmaceuticals NASDAQ:AMPH

$25.53 +1.06 (+4.33%)
Closing price 04:00 PM Eastern
Extended Trading
$25.54 +0.01 (+0.04%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Calliditas Therapeutics AB (publ) stock logo

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)
As of 05/23/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Ocular Therapeutix stock logo

Ocular Therapeutix NASDAQ:OCUL

$6.94 -0.36 (-4.93%)
Closing price 04:00 PM Eastern
Extended Trading
$7.18 +0.23 (+3.39%)
As of 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.